Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease;Utilidad de la olanzapina en la psicosis inducida por levodopa en pacientes Parkinsonianos

Neurologia

Volumn 17, Issue 1, 2002, Pages 7-11

  Chacon J R ^a   Duran E ^a   Duran J A ^a   Alvarez M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Extrapyramidal side effects; Levodopa; Olanzapine; Parkinson's disease; Psychosis

Indexed keywords

LEVODOPA; OLANZAPINE;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; COGNITION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PATIENT MONITORING; PSYCHOSIS; SYMPTOM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 0036323733     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. The management of the levodopa psychosis
2. Treatment of drug induced psychosis in Parkinson's disease with clozapine
3. The use of atypical antipsychotics in the management of schizophrenia
4. Clozapine induced agranulocytosis. Incidence and risk factors in United States
5. Risperidone
6. Risperidone versus clozapine in the treatment of psychosis insix patients with Parkinson's disease and other akynetic-rigid syndromes
7. Treatment of dopaminergic psychosis with olanzapine. Uses and secondary effects
8. Risk factors for nursing home placement in advanced Parkinson's disease
9. Hallucinations in Parkinson's disease: A population study
10. Quetiapine for the treatment of drug induced psychosis in Parkinson's disease
11. The emerging role of clozapine in the tretment of movement disorders
12. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
13. Olanzapine can worsen parkinsonism
14. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease
15. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study
16. Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease
17. Olanzapine as treatment of neuropsychiatry complications of Parkinson's disease: An open label study
18. Olanzapine in the treatment of hallucinosis idiophatic Parkinson's disease: A cautionary note
19. Worsening of motor features of parkinsonism with olanzapine
20. Olanzapine treatment of Parkinson's disease with psychosis
21. Deterioration of parkinsonian symptons following treatment dopaminergic hallucinosis with olanzapine
22. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
23. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
24. Efficacy and safety of clozapine and olanzapine: An open label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
25. Olanzapine for psychosis in Parkinson's disease
26. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
27. Dose-dependent olanzapine associated leukopenia: Three case reports
28. Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia
29. Olanzapine induced leukopenia with human leukocyte antigen profiling
30. Psychosis in neurologic disease: Neurobiology and pathogenesis
31. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopaminergic neurons
32. Olanzapine in the treatment of dopamonimimetic psychosis in patients with Parkinson's disease
33. Radio receptor binding profile of the atypical antipsychotic olanzapine
34. Management of psychosis in Parkinson's disease
35. Olanzapine versus clozapine for hallucinating Parkinson's disease patients. A psychiatrist's perspective
36. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol
37. Olanzapine and models of cognition